American Diabetes Association
Browse
ds23-0040_Supplementary_Appendix_FINAL.pdf (154.32 kB)

Novel Approach to Continuation of Elective Procedures in People at Risk for Sodium–Glucose Cotransporter 2 Inhibitor–Associated Euglycemic Ketoacidosis

Download (154.32 kB)
figure
posted on 2024-03-15, 15:47 authored by Matthew Verdone, Jonathan Bauman, Esben Iversen, Rifka Schulman-Rosenbaum, Anthony Antonacci, Sabatino Leffe, Joseph Simpson, Yael Tobi Harris, Joseph Marino

Diabetes is a common comorbidity among people undergoing elective procedures ranging from screening colonoscopies (1) to joint replacements (2). Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of diabetes pharmacotherapy that help to achieve glycemic control by inhibiting glucose reabsorption in renal tubules (3). The U.S. Food and Drug Administration (FDA) has approved five SGLT2 inhibitors for type 2 diabetes to be used as stand-alone monotherapies or in combination with other pharmacotherapies (4).

Funding

None

History

Usage metrics

    Diabetes Spectrum

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC